Meeting
2011 ASCO Annual Meeting
RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy.
Authors
C. Denkert
Charite Universitaetsmedizin, Berlin, Germany
C. Denkert , R. Kronenwett , S. Loibl , V. Nekljudova , S. Darb-Esfahani , B. Gerber , B. Sinn , C. Petry , I. Bauerfeind , J. Budczies , M. Rezai , M. Dietel , I. Schrader , G. Kunz , G. Von Minckwitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Staging
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10526)
Abstract #
10526
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel
Poster
2019 ASCO Annual Meeting
Race and response to neoadjuvant chemotherapy according to MammaPrint risk.
First Author: Raquel Nunes
Poster
2016 ASCO Annual Meeting
Association between distinct intratumoral and stromal tumor infiltrating immune cells and pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
First Author: Lucia Gonzalez-Cortijo
Poster
2014 ASCO Annual Meeting
Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.
First Author: Maki Tanioka